Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures.
СтатьяНаблюдательное исследованиеПоддержка службы здравоохранения СШАПоддержка NIH: внешняя программаНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kao Chester J, Charmsaz Soren, Alden Stephanie L, Brancati Madelena, Li Howard L, Balaji Aanika, Munjal Kabeer, Howe Kathryn, Mitchell Sarah, Leatherman James, Griffin Ervin, Nakazawa Mari, Tsai Hua-Ling, Danilova Ludmila, Thoburn Chris, Gizzi Jennifer, Gross Nicole E, Hernandez Alexei, Coyne Erin M, Shin Sarah M, Babu Jayalaxmi Suresh, Apostol George W, Durham Jennifer, Christmas Brian J, Konig Maximilian F, Lipson Evan J, Naidoo Jarushka, Cappelli Laura C, Pabani Aliyah, Ged Yasser, Baretti Marina, Brahmer Julie, Hoffman-Censits Jean, Seiwert Tanguy Y, Garonce-Hediger Rachel, Guha Aditi, Bansal Sanjay, Tang Laura, Jaffee Elizabeth M, Chandler G Scott, Mohindra Rajat, Ho Won Jin, Yarchoan Mark
Аннотация
BACKGROUNDImmune-related adverse events (irAEs) and their associated morbidity/mortality are a key concern for patients receiving immune checkpoint inhibitors (ICIs). Prospective evaluation of the drivers of irAEs in a diverse pan-tumor cohort is needed to identify patients at greatest risk and to develop rational treatment and interception strategies.METHODSIn an observational study, we prospectively collected blood samples and performed regular clinical evaluations for irAEs in patients receiving ICI therapy as standard of care for solid tumors. We performed in-parallel analysis of cytokines by Luminex immunoassay and circulating immune cells by cytometry by time-of-flight (CyTOF) at baseline and on treatment to investigate mechanisms of irAEs.RESULTSWe enrolled 111 patients, of whom 40.5% developed a symptomatic irAE (grade ≥ 2). Development of a grade ≥ 2 irAE was positively associated with the use of combination ICI and a history of an autoimmune disorder. Early changes in T helper 17 (Th17) (IL-6, IL-17f), type 2 (IL-5, IL-13, IL-25), and type 1 (TNF-α) cytokine signatures and congruent on-treatment expansions of Th17 and Th2 effector memory (Th2EM) T cell populations in peripheral blood were positively associated with the development of grade ≥2 irAEs. IL-6 levels were also associated with inferior cancer-specific survival and overall survival.CONCLUSIONSIn a diverse, prospective pan-tumor cohort, Th17 and Th2 skewing during early ICI treatment was associated with the development of clinically relevant irAEs but not antitumor responses, providing possible targets for monitoring and therapeutic interventions.FUNDINGJohns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, the NCI SPORE in Gastrointestinal Cancers (P50 CA062924), NCI grant (R50CA243627 to LD), the NIH Center Core Grant (P30 CA006973), Swim Across America (to MY), NIAMS (K23AR075872 to LC), and imCORE-Genentech grant 137515 (to Johns Hopkins Medicine on behalf of MY).